RLMD · Relmada Therapeutics, Inc.

Track RLMD — free

$4.39 -0.16 (-3.41%)

Russell 2000 member Rebalance outlook locked

Market Cap

$475.75M

106.67M

Up next

Next earnings call

Nov 6, 2026 Est · unconfirmed · in 9 wks

Latest filing: 10-Q

filed Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 114 metrics

Revenue (TTM)

$3,166

Trailing 12 months

Net income (TTM)

−$61.93M

Trailing 12 months

Revenue growth YoY

—

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$217.73M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+238.6%

Year over year · more shares

Price change (1Y)

+219.7%

Trailing year

Short interest

12.1%

Latest settlement · 9.4 days to cover

View all 114 metrics

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Sell Momentum Very Weak Sentiment Bullish Fundamentals Weak Quant / Vol Very High

Market backdrop VIX 15.2 · calm Equity put/call 0.56

Technical

price trend

Sell

50 / 200-day cross Death cross

Price vs 200-day avg −17%

below

Price vs 50-day avg −16%

below

RSI (14) 38

neutral

MACD trend Positive

52-week position 49%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Weak

1-month return −17%

trailing

6-month return −26%

trailing

YTD return −6%

this year

Relative strength −41%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) Death cross

50d $5 › 200d $5 — 200d above 50d

Institutional flow Accumulating

+22% holders QoQ · +47 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

12.09% of float · ▼ -4.9% MoM · 9.4 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

127 holders — near 3-yr high, broad support

Squeeze score 61

elevated · 0–100

Fundamentals

Weak

Revenue growth −35%

Y/Y

Gross margin 21%

contracting

EPS growth +45%

Y/Y

Free cash flow $-45.8M

Quant / Vol

risk profile

Very High

Volatility 105%

annualized · 1-yr

Max drawdown −45%

past year

ATR 5.4%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell

3 · 3 · 1

50 / 200-day cross

Death cross Bearish

Price vs 200-day avg

−17% Bearish

Price vs 50-day avg

−16% Bearish

RSI (14)

38 Neutral

MACD trend

Positive Bullish

52-week position

49% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) Death cross

50d $5 › 200d $5 — 200d above 50d

Institutional flow Accumulating

+22% holders QoQ · +47 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

12.09% of float · ▼ -4.9% MoM · 9.4 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

127 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $1 Now $5 · 49% Range high $8

vs 200-day avg -17% vs 50-day avg -16% 50-day below 200-day death cross

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
RLMD Relmada Therapeutics, Inc. this stock	$475.75M	-6.0%	-73.2%	—	12.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$140.51B	+22.8%	+46.2%	32.3	1.6%
REGN Regeneron Pharmaceuticals, Inc.	$84.82B	+10.4%	+20.8%	20.4	2.3%
ARGX Argenx SE	$65.63B	+25.5%	—	—	1.9%
MRNA Moderna, Inc.	$61.59B	+411.4%	+4.3%	—	13.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

127

% held: 94.2%
Net QoQ: +16.4M sh
Top holder: Jupiter Topco LLC

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Falling

Shares short

12.9M

Days to cover: 9.4d
Change: -670.3K sh

View

Short Volume

Short vol %

39%

As of: Sep 2, 2026

Short Total

View

Fails to Deliver

FTD shares

22.5K

Value: $120.8K
As of: Aug 7, 2026

View

Off-Exchange

Off-exchange %

39.2%

Week of: Jul 27, 2026

Off-exch Lit

View

Smart Money

Congressional Trades Sell

Member

Christopher L. Jacobs

Amount: $1.0K–$15.0K
Traded: Dec 12, 2022

View

Financials

Revenue (FY)

$5.1K

Net income (FY): $-57.4M
EPS diluted: $-1.45

View

Buybacks

Remaining

shares 4.0M

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 6, 2026
This year: 11

View

Proposed Sales

Value

$442.5K

Shares: 75.0K
Filed: Feb 20, 2024

View

Earnings & Events

Earnings Calls

Last call

Aug 6, 2026

View

Performance

	5D	20D	120D	MTD	YTD
RLMD	-0.2%	-16.5%	-26.2%	+4.1%	-6.0%
SPY	-0.1%	-0.6%	+14.9%	-0.3%	+12.2%
vs SPY	-0.1%	-15.9%	-41.1%	+4.4%	-18.2%

Capital returns

Buyback program · as of Mar 10, 2014

Authorized

—

Spent (derived)

—

Remaining

shares 4.00M

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1553643 CUSIP 75955J402 13F (30d) 111 filings 110 filers Visit website Investor relations

RLMD · Relmada Therapeutics, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Versus peers

At a glance

Performance

Capital returns